Transfusion therapy in congenital coagulopathies.
Transfusion therapy for the congenital coagulopathies has changed considerably in recent years. Improved donor screening, purification, and virucidal methodologies have resulted in much safer plasma-derived clotting factor concentrates. Additionally, synthetic products such as rF VIII and DDAVP are licensed and available. For persons with hemophilia B, nonthrombogenic coagulation F IX concentrates are available. Treatment recommendations for each of the congenital coagulopathies are discussed.
Wayne State University School of Medicine, Detroit, Michigan.
J M
JM
Lusher
D001323:Autoantibodies; D001778:Blood Coagulation Disorders / Q000151:congenital* / Q000628:therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D016913:Blood Component Transfusion; D005164:Factor IX / Q000276:immunology; D005169:Factor VIII / Q000276:immunology; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy; D006801:Humans; D014842:von Willebrand Diseases / Q000628:therapy
D001323:Autoantibodies; D001779:Blood Coagulation Factors; D005169:Factor VIII; D005164:Factor IX